This article is more than 5 years old. Information may no longer be current.
CDC launches infection control training program, fluoroquinolone use drops following FDA warning – top stories in infectious disease
Click Here to Manage Email Alerts
News that the CDC launched an infection control training program and a study that found fluoroquinolone use decreased after the FDA’s 2016 black box warning were among the top stories in infectious disease last week.
Other top stories included findings that 70% of UTIs were not associated with catheters or other devices, and the FDA’s designation of Ridgeback Biotherapeutics’ investigation Ebola treatment as a breakthrough therapy.
CDC launches infection control training program
National infection prevention experts, led by the CDC’s Health Research & Educational Trust, have developed a new curriculum focused on infection control. Read more.
Fluoroquinolone use decreases following FDA black box warning
The FDA black box warning on fluoroquinolones that was issued in 2016 resulted in a significant, further decline in use at 29 southeastern U.S. hospitals, according to a recent study published in Infection Control and Hospital Epidemiology. Read more.
More than 70% of UTIs not associated with devices
Researchers found that more than 70% of UTIs at University of North Carolina hospitals were not associated with devices, according to recently published study findings. Read more.
FDA grants breakthrough therapy designation to experimental Ebola treatment
The FDA has granted Ridgeback Biotherapeutics breakthrough therapy designation for its investigational Ebola treatment, mAb114, which was recently shown to reduce the mortality rate in patients treated for Ebola during the ongoing outbreak in the Democratic Republic of the Congo. Read more.
Shingrix, Zostavax show promise against herpes zoster in patients with cancer
Both herpes zoster vaccines approved for use in the United States showed promise in preventing the disease in immunocompromised patients with malignancies, according to findings from two phase 3 trials published in The Lancet Infectious Diseases. Read more.